Nissay Asset Management Corp Japan ADV Has $3.72 Million Stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Nissay Asset Management Corp Japan ADV trimmed its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 8.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 34,813 shares of the medical equipment provider's stock after selling 3,375 shares during the period. Nissay Asset Management Corp Japan ADV's holdings in Zimmer Biomet were worth $3,720,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Brookstone Capital Management raised its position in shares of Zimmer Biomet by 34.3% in the fourth quarter. Brookstone Capital Management now owns 8,581 shares of the medical equipment provider's stock worth $906,000 after buying an additional 2,193 shares in the last quarter. Oak Thistle LLC purchased a new stake in shares of Zimmer Biomet in the fourth quarter worth $200,000. Assenagon Asset Management S.A. raised its position in shares of Zimmer Biomet by 1.2% in the fourth quarter. Assenagon Asset Management S.A. now owns 28,490 shares of the medical equipment provider's stock worth $3,009,000 after buying an additional 345 shares in the last quarter. Gateway Investment Advisers LLC raised its position in shares of Zimmer Biomet by 184.9% in the fourth quarter. Gateway Investment Advisers LLC now owns 6,133 shares of the medical equipment provider's stock worth $648,000 after buying an additional 3,980 shares in the last quarter. Finally, Legacy Wealth Asset Management LLC raised its position in shares of Zimmer Biomet by 60.9% in the fourth quarter. Legacy Wealth Asset Management LLC now owns 4,649 shares of the medical equipment provider's stock worth $491,000 after buying an additional 1,759 shares in the last quarter. 88.89% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently commented on ZBH shares. Barclays decreased their price objective on Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating on the stock in a report on Monday, February 10th. JPMorgan Chase & Co. decreased their price objective on Zimmer Biomet from $128.00 to $105.00 and set an "overweight" rating on the stock in a report on Tuesday, May 6th. Morgan Stanley decreased their price objective on Zimmer Biomet from $115.00 to $95.00 and set an "equal weight" rating on the stock in a report on Tuesday, May 6th. Canaccord Genuity Group decreased their price objective on Zimmer Biomet from $115.00 to $101.00 and set a "hold" rating on the stock in a report on Monday, May 12th. Finally, JMP Securities decreased their price objective on Zimmer Biomet from $140.00 to $125.00 and set a "market outperform" rating on the stock in a report on Wednesday, May 7th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, Zimmer Biomet presently has a consensus rating of "Hold" and a consensus target price of $113.45.

Insider Activity

In other news, SVP Lori Winkler sold 1,443 shares of the firm's stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total transaction of $150,649.20. Following the transaction, the senior vice president now owns 8,768 shares in the company, valued at approximately $915,379.20. This trade represents a 14.13% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 1.39% of the stock is owned by insiders.

Zimmer Biomet Trading Down 0.6%

Zimmer Biomet stock traded down $0.56 during midday trading on Tuesday, reaching $95.21. The stock had a trading volume of 2,330,698 shares, compared to its average volume of 1,760,828. The firm's fifty day simple moving average is $103.24 and its two-hundred day simple moving average is $105.76. Zimmer Biomet Holdings, Inc. has a twelve month low of $89.92 and a twelve month high of $120.13. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99. The firm has a market cap of $18.84 billion, a price-to-earnings ratio of 21.40, a PEG ratio of 1.95 and a beta of 0.78.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its earnings results on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. The company had revenue of $1.91 billion during the quarter, compared to analyst estimates of $1.89 billion. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. The company's revenue for the quarter was up 1.1% on a year-over-year basis. During the same quarter last year, the business posted $1.94 EPS. Equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st were issued a dividend of $0.24 per share. The ex-dividend date was Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.01%. Zimmer Biomet's dividend payout ratio is currently 21.24%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.